Sector News

Reuters: Shire moves to prepare Salix bid – sources

February 13, 2015
Life sciences
(Reuters) – British pharmaceutical company Shire Plc (SHP.L) has taken initial steps towards a bid for U.S. bowel drugmaker Salix Pharmaceuticals Inc (SLXP.O) and is working with advisers on a potential offer, according to people familiar with the matter.
 
Shire is evaluating how to secure financing for a Salix bid, one of the sources said. The sources cautioned that Shire may still decide against a bid given the deal’s complexity. Salix is considering its options in the midst of a management shakeup and inventory issues, sources previously told Reuters.
 
Valeant Pharmaceuticals International Inc (VRX.TO) has also been exploring an offer for Salix, the people added. It is not clear whether other companies are also preparing bids for Salix, which has a market capitalization of $9.2 billion.
 
The sources asked not to be identified because the deliberations are confidential. Salix, Shire and Valeant declined to comment.
 
Last November, Salix announced that supply levels for its irritable bowel syndrome drug Xifaxan and other drugs were higher than it had previously indicated, forcing it to slash its full-year earnings forecast.
 
While Salix last month resolved an accounting problem related to its inventory issue, the company may still face other possible fines and litigation that could stymie a potential deal, the sources said. Shares fell 37 percent on the day the company disclosed its inventory issue.
 
Salix Chief Executive Carolyn Logan also stepped down last month following the departure of other top executives.
 
The company said in late January it would restate financial statements for all of 2013 and the first three quarters of 2014.
 
Shire has made several acquisitions to bolster its focus on rare diseases, including a $5.2 billion acquisition of NPS Pharmaceuticals in January and a $4.2 billion acquisition of ViroPharma last year.
 
Rare diseases remain an attractive area of focus for pharmaceutical companies because there are fewer hurdles to regulatory approval, marketing costs are lower and drug prices are higher than with mainstream drugs.
 
Jefferies analyst David Steinberg wrote in a December note to clients that a takeover of Salix by Shire would be a “strong fit,” because of the two companies’ complementary gastro-intestinal drug portfolios.
 
(Reporting by Olivia Oran in New York; Editing by Bernard Orr)

comments closed

Related News

September 17, 2022

Novo Nordisk partners with Microsoft for AI-driven drug discovery

Life sciences

Novo Nordisk has signed a new strategic partnership with Microsoft to expedite the discovery and development of drugs leveraging big data and artificial intelligence (AI). Under the deal, Microsoft’s computational services, Cloud and artificial intelligence (AI) will be merged with the drug discovery, development and data science expertise of Novo Nordisk.

September 17, 2022

Bayer’s hunt for a new CEO is on, suggesting Werner Baumann could be headed for an early exit: report

Life sciences

Following years of push-and-pull over the German conglomerate’s top post, Bayer has quietly started a hunt for Baumann’s successor, Bloomberg News reported Tuesday, citing people close to the matter. The new CEO search may portend an early departure for Baumann, whose contract with Bayer isn’t set to expire until April 2024.

September 17, 2022

Bluebird CFO resigns ahead of gene therapy launch

Life sciences

Bluebird bio on Monday said its chief strategy and financial officer, Jason Cole, will leave the company this fall, marking the second time in less than a year the cash-strapped gene therapy developer will replace its top financial executive.